Human Papillomavirus 16, 18, and 33 Infections and Risk of Prostate Cancer: A Nordic Nested Case-Control Study

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 14; no. 12; pp. 2952 - 2955
• Main Authors: Korodi, Zoltan, Dillner, Joakim, Jellum, Egil, Lumme, Sonja, Hallmans, Göran, Thoresen, Steinar, Hakulinen, Timo, Stattin, Pär, Luostarinen, Tapio, Lehtinen, Matti, Hakama, Matti
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.12.2005
• Subjects: Adult; Biological and medical sciences; Cancer and Oncology; Cancer och onkologi; Case-Control Studies; Clinical Medicine; Descriptive, Risk Factor, and Methodologic Studies; DNA tumor viruses; Enzyme-Linked Immunosorbent Assay; Genitourinary cancers: prostate; Human papillomavirus 16; Human papillomavirus 16 - pathogenicity; Human papillomavirus 18; Human papillomavirus 18 - pathogenicity; Human papillomavirus 33; Human tumor viruses; Humans; Infections and the etiology of cancer; Klinisk medicin; Logistic Models; Male; Medical and Health Sciences; Medical sciences; Medicin och hälsovetenskap; Middle Aged; Nephrology. Urinary tract diseases; Papillomavirus Infections - complications; Papillomavirus Infections - epidemiology; Papillomavirus Infections - virology; Papillomavirus Infections/complications/epidemiology/virology; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - virology; Prostatic Neoplasms/epidemiology/virology; Registries; Risk Factors; Scandinavia/epidemiology; Scandinavian and Nordic Countries - epidemiology; Seroepidemiologic Studies; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Sweden; Norway; Scandinavia; Europe; Finland; Scandinavian and Nordic Countries; Human; Urinary system disease; Prostate disease; Papovaviridae; Malignant tumor; Case control study; Epidemiology; Human papillomavirus 18; Infection; Papillomavirus; Virus; Human papillomavirus 16; Human papillomavirus; Cancerology; Viral disease; Risk factor; Male genital diseases; Prostate cancer; Public health
• ISSN: 1055-9965; 1538-7755; 1538-7755
• DOI: 10.1158/1055-9965.EPI-05-0602

Epidemiologic evidence of sexual history has emerged as a consistently found risk factor for prostate cancer. Some studies have reported an association between human papillomavirus (HPV) infections and prostate cancer. We did a nested case-control study within cohorts of more than 200,000 men enrolled in three Nordic biobanking projects. Follow-up using cancer registry linkages identified 804 prospectively occurring prostate cancer cases. Four control subjects per case were randomly selected from eligible sets of matched subjects that were alive and free of cancer at the time of diagnosis of the corresponding case and were matched to cases on biobank cohort, age (±2 years), county of residence, and date of blood sampling (±2 months in the Finnish and Swedish cohorts, ±6 months in the Norwegian cohort). The serum samples were analyzed by standard ELISAs for the presence of immunoglobulin G antibodies against HPV types 16, 18, and 33. The joint HPV-16/HPV-18/HPV-33 seroprevalence in the joint cohort was 13.4% (107 of 799) among cases and 14.0% (363 of 2,596) among controls (odds ratio, 0.94; 95% confidence interval, 0.74-1.19). There were no noteworthy differences when the data were analyzed by different HPV type, country, or antibody levels. Our data do not support an association between serologic markers of HPV-16, HPV-18, and HPV-33 infections and risk of prostate cancer. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2952–5)